Palavras-chave
Metilfenidato
Efeitos adversos
Pediatria
Como Citar
Resumo
Introdução: O transtorno de déficit de atenção com hiperatividade (TDAH) é um diagnóstico frequente na pediatria, sendo causado, sobretudo, por dificuldade de atenção, hiperatividade e impulsividade. O objetivo deste estudo foi discutir as complicações relacionadas ao uso de Metilfenidato como tratamento do TDAH, na pediatria, a fim de amenizar os efeitos adversos e conquistar a melhor terapêutica. Metodologia: Trata-se de uma revisão integrativa de literatura. Foi utilizada a plataforma de Descritores em Ciências da Saúde (DeCS/MeSH), aplicando os descritores “ADHD” AND “Methylphenidate” AND “Complications” AND “Children”, tanto na língua inglesa, quanto na língua portuguesa. Foi realizada uma pesquisa nas bases de dados: PubMed, BVS e Scopus, obtendo 140 estudos. Os critérios de inclusão são os artigos estudos “free full text”, dos últimos 5 anos que respondem à pergunta de pesquisa e são da língua portuguesa ou inglesa. Dessa forma, permaneceram incluídos 37 artigos, dos quais 11 eram duplicados, restando 26 a serem inseridos nesta pesquisa. Resultados: Observou-se a presença de efeitos adversos associados ao uso de Metilfenidato em pacientes pediátricos diagnosticados com Transtorno do Déficit de Atenção e Hiperatividade, tais como redução do tempo de sono, restrição do crescimento, deficiências oculares e agitação. Conclusão: Assim, foi possível perceber que existem diversas repercussões associadas ao uso do Metilfenidato em pacientes pediátricos portadores de TDAH. Diante desses efeitos multifatoriais, é necessário entender o quadro de cada paciente, com o propósito de encontrar a melhor abordagem terapêutica e mitigar os resultados desfavoráveis relacionados ao uso do Metilfenidato.
Referências
Ornoy A, Koren G. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 2021;19(11):1794-1804. doi: 10.2174/1570159X18666201127164000. PMID: 33245274; PMCID: PMC9185785.
Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.
Leffa DT, Caye A, Rohde LA. ADHD in Children and Adults: Diagnosis and Prognosis. Curr Top Behav Neurosci. 2022;57:1-18. doi: 10.1007/7854_2022_329. PMID: 35397064.
Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. PMID: 34174276.
GANONG, L. H. Integrative reviews of nursing research. Research in Nursing & Health, v. 10, n. 1, p. 1–11, fev. 1987
SOUZA, Marcela Tavares de; SILVA, Michelly Dias da ; CARVALHO, Rachel de. Integrative Review: What Is It? How to Do It? Einstein (São Paulo), v. 8, n. 1, p. 102–106, 2010. Disponível em: <https://doi.org/10.1590/s1679-45082010rw1134>.
TSUJII, N. et al. Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review. Neurology and Therapy, v. 10, n. 2, p. 499–522, 4 jun. 2021.
ROSENAU, P. T. et al. Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Psychiatric Research, v. 152, p. 31–37, 1 ago. 2022.
LILJA, M. M. et al. The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort. Journal of Neurodevelopmental Disorders, v. 14, n. 1, p. 17, 6 mar. 2022.
KARAHMADI, M.; SAADATMAND, S.; TARAHI, M. J. Investigation of Efficacy of Short-Acting Methylphenidate (Ritalin) and Long-Acting (Matoride) on Symptoms of Attention Deficit Hyperactivity Disorder in Children Aged 6–18 Years: A Single-Blind, Randomized Clinical Trial. Advanced Biomedical Research, v. 9, n. 1, 29 maio 2020.
EATON, C. et al. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy. Cochrane Database of Systematic Reviews, v. 2022, n. 7, 13 jul. 2022.
AYDEMIR, E.; AYDEMIR, G. A.; KALINLI, M. Evaluation of ocular surface in children with attention deficit hyperactivity disorder with respect to methylphenidate treatment. Arquivos Brasileiros de Oftalmologia, 23 set. 2022.
MOHAMMADZADEH, S. et al. Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics, v. 62, n. 9, p. 360–366, 1 set. 2019.
PAI, L.-F. et al. New insights into precocious puberty and ADHD: a nationwide cohort study. Pediatr Res, p. 1787–1794, dez. 2022.
CHEN, V. C.-H. et al. Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. Eur Child Adolesc Psychiatry, p. 361–368, fev. 2022.
KUROKAWA, S. et al. Gastrointestinal symptoms and sensory abnormalities associated with behavioral problems in children with neurodevelopmental disorders. Autism Res, p. 1996–2001, set. 2021.
ROCHE, M. et al. Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. J Intellect Disabil Res, p. 795–800, 2021.
JOSHI, G.; WILENS, T. E. Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am, p. 449–468, 2022.
LEEMAN-MARKOWSKI, B. A. et al. Methylphenidate for attention problems in epilepsy patients: Safety and efficacy. Epilepsy Behav, p. 107627–107627, 2021.
MILLER, J.; PERERA, B.; SHANKAR, R. Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Expert Opin Pharmacother, p. 1897–1913, 2020.
DEFRODA, S. F. et al. The effects of methylphenidate on stress fractures in patients’ ages 10-29: a national database study. Phys Sportsmed, p. 412–416, 2020.
KAALUND-BROK, K. et al. Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD. PLOS ONE, v. 16, n. 10, p. e0253727, 21 out. 2021.
OUADIH-MORAN, M. et al. Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and ω-3 PUFAs. Nutrients, v. 15, n. 3, p. 712–712, 31 jan. 2023.
MAEDER, J. et al. Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial. The International Journal of Neuropsychopharmacology, v. 25, n. 3, p. 215–225, 17 mar. 2022.
AKKAYA, S. et al. Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder. Indian Journal of Ophthalmology, v. 69, n. 12, p. 3607, 1 dez. 2021.
BINGÖL-KIZILTUNÇ, P.; YÜRÜMEZ, E.; ATILLA, H. Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study. Indian Journal of Ophthalmology, v. 70, n. 5, p. 1664–1668, 1 maio 2022.
SASAKI, Y. et al. Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan. PLOS ONE, v. 16, n. 6, p. e0252420, 3 jun. 2021.
TSO, W. et al. Early sleep deprivation and attention-deficit/hyperactivity disorder. Pediatric Research, v. 85, n. 4, p. 449–455, 1 mar. 2019.
ARAIN, F. et al. Stimulant induced Dermatological and Vascular Complications in patients with ADHD: A literature review. European Psychiatry, v. 65, n. S1, p. S420–S420, 1 jun. 2022.
BRIKELL, I. et al. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. American Journal of Psychiatry, v. 178, n. 9, p. appi.ajp.2020.2, 22 jun. 2021.
SANABRA, M. et al. Deficient Emotional Self-Regulation and Sleep Problems in ADHD with and without Pharmacological Treatment. Journal of Attention Disorders, p. 108705472098624, 20 jan. 2021.
ROSS, L. et al. Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses. CNS Drugs, v. 34, n. 6, p. 643–649, 16 abr. 2020.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Amanda Safira Araújo Mendes, Anne Caroline D’avila Pinheiro Daniel, Marianna Carla Santos Maciel, Rodrigo Dantas do Nascimento Filho, Luanny Rabelo Dantas Maia Patrício de Figueiredo, Vinicius Augusto Santos Varela Barca Bacurau, Maria Oitava Rosado Cantídio, Ana Larissa Fernandes De Holanda Soares